Roivant Sciences Ltd. (NASDAQ:ROIV) Q1 2025 Earnings Conference Call August 8, 2024 8:00 AM ET

Company Participants

Stephanie Lee - Investor Relations
Matt Gline - Chief Executive Officer

Conference Call Participants

Allison Bratzel - Piper Sandler
Brian Cheng - JPMorgan
Dave Risinger - Leerink Partners
Dennis Ding - Jefferies
Yaron Werber - TD Cowen
Louise Chen - Cantor
Yatin Suneja - Guggenheim
Douglas Tsao - H.C. Wainwright
Andy Chen - Wolfe Research

Operator

Good day and thank you for standing by. Welcome to the Roivant First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Stephanie Lee. Please go ahead.

Stephanie Lee

Good morning, and thank you for joining today's call to review Roivant's financial results for the first quarter ended June 30, 2024 along with the business update. I'm Stephanie Lee with Roivant. Presenting today, we have Matt Gline, CEO of Roivant.

For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the slide numbers as we present to help you follow along.

I'd like to remind you that we'll be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we have filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties.

And with that, I'll turn it over to Matt.

Matt Gline

Great. Thanks, Steph, and thanks everybody for joining. It's always a pleasure to get on these calls. In truth, we saved all of our fund updates for this fall. So today is a relatively straightforward set of updates but a couple of really meaningful clinical execution points and a couple of other things that I'm happy to be talking about. So thank you again.

I'll start just quickly on slide 5 in the deck with a reminder. Just kind of where we are this year which is, this is a year of growth and expansion for us. So we're focused very much on delivering clinical data across multiple of our franchise the anti-FcRn franchise where we have some meaningful data sets that's coming as soon as -- the near future as well as over the next call it six months.